Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $60.33.
A number of brokerages have weighed in on SLNO. Robert W. Baird started coverage on Soleno Therapeutics in a report on Friday, May 10th. They set an “outperform” rating and a $72.00 price target for the company. Oppenheimer cut their price objective on shares of Soleno Therapeutics from $65.00 to $59.00 and set an “outperform” rating on the stock in a research report on Monday, May 13th. Finally, Baird R W raised shares of Soleno Therapeutics to a “strong-buy” rating in a research report on Friday, May 10th.
Check Out Our Latest Analysis on Soleno Therapeutics
Insider Activity at Soleno Therapeutics
Institutional Investors Weigh In On Soleno Therapeutics
Several large investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its stake in shares of Soleno Therapeutics by 28.6% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 133,584 shares of the company’s stock worth $5,450,000 after purchasing an additional 29,745 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Soleno Therapeutics during the 2nd quarter worth approximately $3,623,000. Assenagon Asset Management S.A. purchased a new stake in shares of Soleno Therapeutics during the 2nd quarter worth approximately $29,778,000. SG Americas Securities LLC purchased a new stake in shares of Soleno Therapeutics during the 2nd quarter worth approximately $569,000. Finally, California State Teachers Retirement System increased its stake in shares of Soleno Therapeutics by 33.8% during the 1st quarter. California State Teachers Retirement System now owns 13,780 shares of the company’s stock worth $590,000 after purchasing an additional 3,481 shares during the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.
Soleno Therapeutics Trading Down 0.3 %
Shares of Soleno Therapeutics stock opened at $46.66 on Wednesday. The business has a 50-day moving average price of $43.84 and a two-hundred day moving average price of $44.30. Soleno Therapeutics has a 1-year low of $3.69 and a 1-year high of $53.82. The company has a market cap of $1.56 billion, a P/E ratio of -17.41 and a beta of -1.39.
Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.29). Equities research analysts forecast that Soleno Therapeutics will post -2.36 EPS for the current fiscal year.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
See Also
- Five stocks we like better than Soleno Therapeutics
- How to Invest in the FAANG Stocks
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Do ETFs Pay Dividends? What You Need to Know
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Insider Trades May Not Tell You What You Think
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.